Contribution of anaemia to progression of renal disease: A debate

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 1, 2002, Pages 60-66

  Rossert, Jérôme A ^a   McClellan, W M ^b   Roger, S D ^c   Verbeelen, D L ^d   Horl W H ^e  

^a HÔPITAL TENON   (France)

^b Georgia Medical Care Foundations   (United States)

^c GOSFORD HOSPITAL   (Australia)

^d Academisch Ziekenhuis   (Belgium)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anaemia; Blood pressure; Epoetin; r HuEPO; Renal failure

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD PRESSURE REGULATION; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; HYPOTHESIS; HYPOXIA; KIDNEY BLOOD VESSEL; KIDNEY CELL; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE CELL; KIDNEY TUBULE DISORDER; META ANALYSIS; METHODOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; THEORY; VASOCONSTRICTION;

EID: 0036178363     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_1.60     Document Type: Article

References (44)

1. Oxidative stress in anaemia
2. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1
3. L and Bcl-2
4. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines
5. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
6. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
7. Effect of recombinant human erythropoietin on endothelial cell apoptosis
8. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway
9. Human, rat and mouse kidney cells express functional erythropoietin receptors
10. Low oxygen tension increases mRNA levels of alpha 1 (I) procollagen in human dermal fibroblasts
11. Stimulation of collagen synthesis in rat cardiac fibroblasts by exposure to hypoxic culture conditions and suppression of the effect by natriuretic peptides
12. Hypoxia promotes fibrogenesis in human renal fibroblasts
13. Hypoxic induction of prolyl 4-hydroxylase alpha (I) in cultured cells
14. Regulation of collagen synthesis by ascorbic acid: Characterization of the role of ascorbate-stimulated lipid peroxidation
15. D-alpha-tocopherol inhibits collagen alpha 1 (I) gene expression in cultured human fibroblasts. Modulation of constitutive collagen gene expression by lipid peroxidation
16. Redox regulation of renal DNA synthesis, transforming growth factor-beta 1 and collagen gene expression
17. Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells
18. Interstitial fibrosis in hypercholesterolemic rats: Role of oxidation, matrix synthesis and proteolytic cascades
19. Mechanisms of tubulo-interstitial injury in progressive renal diseases
20. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia
21. Contribution of tubular injury to loss of remnant kidney function
22. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats
23. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor
24. Cell apoptosis and proliferation in experimental chronic obstructive uropathy
25. 2+ channels: Activation by phospholipase C-gamma 1
26. Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats
27. Nitric oxide metabolism in erythropoietin-induced hypertension: Effect of calcium channel blockade
28. Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans
29. Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetylcholine
30. Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension
31. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin
32. Evidence of renal vasodilatation in pre-dialysis patients during correction of anemia by erythropoietin
33. Anaemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass
34. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model
35. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients
36. Effect of recombinant human erythropoietin on renal function in humans
37. Effectiveness and safety of recombinant human erythropoietin in predialysis patients
38. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure
39. Renal function in predialysis children with chronic renal failure treated with erythropoietin
40. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
41. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients
42. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients
43. Reversal of anaemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
44. Use of erythropoietin before initiation of dialysis and its impact on mortality